Drug Discovery
6 stories in this blend
There's An AI For That·3d agoAI Model Attempts Autonomous Molecule Design for Scorpion Antivenom
Researchers used a custom setup of Anthropic's Claude to design molecular binders capable of targeting scorpion venom toxins. Running across hundreds of software instances, the model created thousands of candidates, several of which successfully bound to specific target toxins in lab tests. However, it failed to produce a universal antivenom capable of neutralizing multiple toxins simultaneously.
The Neuron·Sep 30Isomorphic Labs applies automated agents to drug discovery
Isomorphic Labs used an autonomous research agent to search expansive chemical libraries for balanced drug candidates. The system evaluated structural tradeoffs, though the firm has not yet designated specific medical targets for clinical trials.
The Neuron·Sep 22Researchers launch RetroChimera model for chemical compound synthesis
Microsoft Research partnered with pharmaceutical firms GSK and Novartis to launch RetroChimera, an AI system trained on drug discovery data. The model demonstrates improved predictions for synthesized molecular structures using proprietary and open research datasets.
Superintelligence·Sep 10AI created therapeutic demonstrates secondary effects on biological aging markers
A trial evaluating rentosertib, a drug designed by artificial intelligence for lung disease, showed significant reductions in blood protein indicators associated with biological age. Across six measurement models, treated patients showed profile changes resembling younger cellular states.
Superhuman·Sep 8Experimental AI designed medication shows potential in anti aging trial
In a 12 week clinical study involving 42 participants, a drug developed by Insilico Medicine demonstrated reductions in measured biological age across six testing metrics. Originally created for lung disease, the therapeutic compound requires extensive additional trials because biological age measurements are not yet standardized.
The Neuron·Sep 8AI designed lung drug shows signs of reversing biological age markers
Blood samples from a clinical trial for lung disease drug rentosertib were evaluated using six proteomic aging clocks. Results showed that participants taking the AI designed medication lowered their biological age estimates by three to six years depending on the measurement system used.
